Effect of Thalidomide in Covid 19 pneumonia
Phase 3
Completed
- Conditions
- Pneumonia caused by Coronavirus 2019, COVID19.Coronavirus infection, unspecifiedB34.2
- Registration Number
- IRCT20200428047232N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
18-75 year old men and 50-75 year old women admitted in hospital
Percentage of oxygen saturation at the time of admission: 89-85% (provided it is modified with Nazal auxiliary oxygen to more or equal to 90%) or oxygen saturation percentage of 90-93% and the number of breaths per minute more or equal to 30
Clinical manifestations associated with COVID-19 pneumonia with positive PCR test or HR-CT scan
Exclusion Criteria
Previous Chronic lung disease
Multi-organ failure at admission
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to reach clinical recovery. Timepoint: Daily visit in the hospital every 8 hours by the physician. Method of measurement: Pulse oximetery device.
- Secondary Outcome Measures
Name Time Method 28 days survival rate. Timepoint: Weekly up to 4 weeks from the time of hospitalization to 4 weeks after discharge. Method of measurement: Telephone call.